<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519817</url>
  </required_header>
  <id_info>
    <org_study_id>120056</org_study_id>
    <secondary_id>12-C-0056</secondary_id>
    <nct_id>NCT01519817</nct_id>
  </id_info>
  <brief_title>Cancer Vaccine Targeting Brachyury Protein in Tumors</brief_title>
  <official_title>An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Cancer vaccines are being developed to help teach the body's immune system to attack and
      destroy cancer cells. A new vaccine being tested targets Brachyury protein. This protein is
      present in some tumor cells, and it can help tumor cells spread to other parts of the body.
      Researchers want to see whether the new Brachyury protein vaccine can help treat people with
      advanced carcinomas.

      Objectives:

      - To test the safety and effectiveness of a cancer vaccine that targets Brachyury protein in
      tumor cells.

      Eligibility:

        -  Individuals at least 18 years of age who have advanced cancers that have not responded
           or are no longer responding to standard treatments.

        -  Because the vaccine is made with yeast, people with yeast allergies will not be
           eligible.

      Design:

        -  Participants will be screened with a medical history and physical exam. Imaging studies
           will be used to examine the cancer. Heart and thyroid function tests will be conducted.
           Blood and urine samples will also be collected.

        -  Participants will receive vaccine injections every 2 weeks, for a total of seven visits.
           After seven visits, if the cancer has shrunk or stopped growing, participants will
           continue to have the vaccine about once a month.

        -  Treatment will be monitored with frequent blood tests and imaging studies. Other tests
           will be given as directed by the study doctors. Some participants will have apheresis to
           collect additional blood cells for study.

        -  Participants will continue to receive the vaccine as long the tumor does not start
           growing again and there are no serious side effects....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Vaccines based on recombinant heat inactivated yeast have been shown to be immunogenic
           and well tolerated in animals and humans.

        -  Using a computer-based differential display analysis tool to conduct global comparison
           of expressed sequence tag (EST) clusters in the Unigene database, the gene encoding for
           the transcription factor Brachyury was identified as highly represented in tumor-derived
           libraries and rarely observed in normal tissue-derived libraries. By using
           reverse-transcription followed by polymerase chain reaction (RT-PCR), investigators in
           the LTIB have identified the overexpression of Brachyury in gastrointestinal, bladder,
           kidney, ovary, uterus, and testicular carcinomas. Similar studies also found
           over-expression of Brachyury mRNA in cell lines of lung, colon and prostate cancers, but
           not in the majority of normal tissues tested, with the exception of expression in the
           testis, thyroid and low levels of expression in B cells pooled from multiple normal
           donors.

        -  Brachyury is a member of the T-box family of transcription factors, characterized by a
           highly conserved DNA-binding domain designated as T-domain. Data indicates that the
           transcription factor Brachyury confers on the tumor cells a mesenchymal phenotype, as
           well as migratory and invasive abilities and enhances tumor cell progression.

        -  A murine model of MC38 cells engineered to over express human Brachyury gene has
           demonstrated increased metastatic potential of Brachyury over-expressing MC38 cells.

        -  Brachyury specific T cells can lyse human cancer cells expressing Brachyury in an MHC
           restricted manner.

        -  GI-6301 (Yeast-Brachyury vaccine) has been tested in vitro and in the mouse model. These
           studies showed Brachyury-specific T cell responses and decreased metastasis in mice
           treated with vaccine.

        -  An ongoing study of a Hepatitis B vaccine (GS-4774) using the yeast platform (heat
           killed Saccharomyces cerevisiae) indicated safety of 80 YU dose (4 injection sites at 20
           YU injections per site).

      Objectives:

      -The primary objectives are to:

        -  Determine the safety and tolerability of escalating doses of GI-6301 (Yeast-Brachyury
           vaccine) a heat-killed yeast-based vaccine

        -  Determine in an expanded cohort if a significant change in Brachyury specific T cells
           will be detectable post vaccine.

      Eligibility:

        -  Adults with histologically proven metastatic or locally advanced solid tumors for which
           standard curative or palliative measures are no longer effective. Efforts will be made,
           as much as possible, to enroll patients with tumor types with known increased expression
           of Brachyury (such as lung, breast, ovarian, prostate, colorectal, pancreatic or
           chordoma).

        -  Adequate organ function as defined by liver, kidney, and hematologic laboratory testing.

        -  Patients with acquired immune defects, systemic autoimmune disease, concurrent use of
           steroids, pericardial mass &gt; 1 cm, chronic infections, concurrent tricyclic
           antidepressant therapy, or allergy to yeast or yeast-based products will be excluded.

      Design:

        -  This is an open label, phase I trial with sequential dose escalation cohorts of patients
           (3-6 patients per dose cohort) for 3 doses of GI-6301 (Yeast-Brachyury vaccine).

        -  GI-6301 (Yeast-Brachyury vaccine) will be administered subcutaneously at 4 sites
           biweekly for 7 visits (day 1, 15, 29, 43, 57, 71, 85), then monthly until patients meet
           off-study criteria

      (patients who have been on study for one year or more and have had stable disease or better
      (PR, CR) have the option to receive vaccine once every 3 months instead of monthly).

        -  All patients on a given dose level will have completed 28 days on-study without DLT
           before enrollment can begin on the next dose level or on the expansion phase (see
           statistical analysis section).

        -  Expansion Phase: 10 additional patients will be enrolled on the MTD dose level (or the
           highest dose level explored in the event that a true MTD is not reached), receiving the
           same treatment regimen, to assess for immunologic responses and clinical responses.

        -  Amended dose escalation: 10 patients will be enrolled at an additional dose level (80 YU
           per dose, 4 injection sites at 20 YU per site) to determine the safety of this dose
           level.

        -  Up to 33 total patients may be required to complete enrollment of this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2012</start_date>
  <completion_date type="Actual">September 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 3, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Brachyury-Specific T-cell Responses</measure>
    <time_frame>Baseline (pre-vaccination) and approximately day 84 (after 6 vaccinations)</time_frame>
    <description>A fluorescense activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine</measure>
    <time_frame>4 years and 25 days</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. A non-serious adverse event is any untoward medical occurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>3 and 5 months restaging</time_frame>
    <description>Clinical benefit is defined as partial response (PR) or stable disease (SD) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial response is ≥30% decrease in the sum of greatest diameters/no new lesions. Progressive disease is ≥20% increase in the sum of greatest diameters/new lesions. Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response, or progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)</measure>
    <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
    <description>Blood samples will be collected via apheresis and analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC), Tregs, CD4 central memory (CD4 CM), CD4 effector memory (CD4 EM), CD4 terminal effector memory (CD4 EMRA), CD4 naïve, CD8 CM, CD8 EM, CD8 EMRA, and CD8 naïve cells. Significance of changes in immune cells was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Levels of Cytokines</measure>
    <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
    <description>Blood samples were collected and changes in serum levels of cytokines interferon gamma (IFNg), Interleukin 10 (IL-10), Interleukin 12 (IL-12)p70, Interleukin 1b (IL-1b), Interleukin 2 (IL-2), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and tumor necrosis factor (TNF) were assessed by the multiplexed mesoscale assay. Significance of changes in serum levels of cytokines was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Soluble Cluster of Differentiation 27 (sCD27)</measure>
    <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
    <description>Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27 was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L)</measure>
    <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
    <description>Blood samples were collected and changes in serum levels of the ratio of soluble sCD27:sCD40L was assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27:sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Soluble Cluster of Differentiation 40L (sCD40L)</measure>
    <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
    <description>Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Neoplasms</condition>
  <condition>Malignant Solid Tumors</condition>
  <condition>Colon Neoplasms</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Yeast-Brachyury vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301 (Yeast Brachyury Vaccine)</intervention_name>
    <description>GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.</description>
    <arm_group_label>Yeast-Brachyury vaccine</arm_group_label>
    <other_name>Yeast-Brachyury vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Participants must meet the following criteria for participation:

          -  Diagnosis: Patients must have histologically confirmed malignancy by the Laboratory of
             Pathology, National Cancer Institute (NCI), that is metastatic or unresectable locally
             advanced malignant solid tumor. In the case of Chordoma, unresectable, locally
             recurrent, or metastatic tumors are acceptable for enrollment, given that this
             represents incurable disease. Efforts will be made, as much as possible, to enroll
             patients with tumor types with known increased expression of Brachyury (such as lung,
             breast, ovarian, prostate, colorectal, pancreatic, or chordoma).

          -  Patients may have disease that is measurable or non-measurable but evaluable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry
             (Karnofsky greater than or equal to 70)

          -  Age greater than or equal to 18 years. Because no dosing or adverse event data are
             currently available on the use of Yeast Brachyury vaccine in patients &lt;18 years of
             age, children are excluded from this study, but will be eligible for future pediatric
             trials.

          -  Prior Therapy: Completed or had disease progression on at least one prior line of
             diseaseappropriate therapy for metastatic disease, or not be a candidate for therapy
             of proven efficacy for their disease.

          -  Patients must have normal organ and marrow function as defined below:

               -  Serum creatinine 1.5 times upper limit of normal OR creatinine clearance on a
                  24-h urine collection of 60 mL/min.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 times the
                  upper limits of normal.

               -  Total bilirubin less than or equal to 1.5 times upper limit of normal OR in
                  patients with Gilbert's syndrome, a total bilirubin 3.0.

               -  Hematological eligibility parameters (within16 days of starting therapy):

               -  Granulocyte count 1,500/mm(3)

               -  Platelet count 100,000/m(3)

               -  Patients must have baseline pulse oximetry &gt; 90% on room air.

          -  Recovered completely (Grade 1 or baseline) from any reversible toxicity associated
             with recent therapy. Typically this is 3 4 weeks for patients who most recently
             received cytotoxic therapy, except for the nitrosoureas and mitomycin C for which 6
             weeks is needed for recovery.

          -  There should be a minimum of 2 weeks from any prior chemotherapy, immunotherapy and/or
             radiation.

          -  Prior immune therapy is allowed.

          -  Men and women of child-bearing potential must agree to use effective birth control or
             abstinence during and for a period of 4 months after the last vaccination therapy.

          -  Patients with prostate cancer must continue to receive gonadotropin-releasing hormone
             (GnRH) agonist therapy (unless orchiectomy has been done). If a patient has refused
             GnRH therapy, they may be enrolled on a dose level for which the safety has already
             been determined.

          -  Patients with estrogen-receptor positive (ER+) breast cancer being treated with
             adjuvant hormonal therapy (selective estrogen receptor modulator or aromatase
             inhibitor) who have rising tumor markers as evidence of disease progression or
             metastatic disease on scans may continue on hormonal therapy while being treated with
             vaccine.

          -  Patients must be negative for yeast allergy skin test

          -  Ability to understand and the willingness to sign a written informed consent document.

        EXCLUSION CRITERIA:

        Patients with any of the following will not be eligible for participation in this study:

        - Patients should have no evidence of immune dysfunction as listed below.

          -  Human immunodeficiency virus (HIV) positivity due to the potential for decreased
             immune response to the vaccine.

          -  Active autoimmune diseases requiring treatment or a history of autoimmune disease that
             might be stimulated by vaccine treatment. This requirement is due to the potential
             risks of exacerbating autoimmunity. However, patients with vitiligo, diabetes
             mellitus, and hashimoto s thyroiditis on appropriate replacement therapy may be

        enrolled.

        --Concurrent use of systemic steroids, except for physiologic doses of systemic steroid
        replacement or local (topical, nasal, or inhaled) steroid use. Limited doses of systemic
        steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent
        intravenous (IV) contrast allergic reaction or anaphylaxis in patients who have known
        contrast allergies) are allowed.

          -  History of allergy or untoward reaction to yeast-based products (any hypersensitivity
             to yeast-based products will be excluded).

          -  Pregnant or breast-feeding women, due to the unknown effects of the Yeast Brachyury
             vaccine on the fetus or infant.

          -  Serious intercurrent medical illness which would interfere with the ability of the
             patient to carry out the treatment program, including, but not limited to,
             inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active
             diverticulitis.

          -  Untreated brain metastases (or local treatment of brain metastases within the last 6
             months) and or spinal cord metastasis.

          -  Patients with pericardial masses &gt;1 cm will be excluded.

          -  Concurrent chemotherapy. (However, the following anti-tumor therapies will be allowed:
             Trastuzumab for human epidermal growth factor receptor 2 (HER2+) breast cancer and
             hormonal therapy for breast (e.g., selective estrogen receptor modulators, aromatase
             inhibitors) and prostate cancer (e.g., GnRH antagonists/agonists or antagonists and
             androgen receptor antagonists).

          -  Chronic hepatitis infection, including B and C, because potential immune impairment
             caused by these disorders may diminish the effectiveness of this immunologic therapy.

          -  Patients requiring continuous tricyclic antidepressant therapy should be excluded due
             to the interference with the yeast skin test in creating false negative test results.

          -  Participation in another interventional clinical trial within 28 days before start of
             study treatment.

          -  Any significant disease that, in the opinion of the investigator, may impair the
             patient s tolerance of study treatment.

          -  Significant dementia, altered mental status, or any psychiatric condition that would
             prohibit the understanding or rendering of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Gulley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-C-0056.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Baranova AV, Lobashev AV, Ivanov DV, Krukovskaya LL, Yankovsky NK, Kozlov AP. In silico screening for tumour-specific expressed sequences in human genome. FEBS Lett. 2001 Nov 9;508(1):143-8.</citation>
    <PMID>11707285</PMID>
  </reference>
  <reference>
    <citation>Krukovskaja LL, Baranova A, Tyezelova T, Polev D, Kozlov AP. Experimental study of human expressed sequences newly identified in silico as tumor specific. Tumour Biol. 2005 Jan-Feb;26(1):17-24. Epub 2005 Feb 28.</citation>
    <PMID>15741768</PMID>
  </reference>
  <reference>
    <citation>Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007 Apr 15;13(8):2471-8.</citation>
    <PMID>17438107</PMID>
  </reference>
  <results_reference>
    <citation>Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.</citation>
    <PMID>26130065</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <results_first_submitted>February 27, 2017</results_first_submitted>
  <results_first_submitted_qc>May 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>James Gulley, M.D.</investigator_full_name>
    <investigator_title>Senior Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccine Therapy</keyword>
  <keyword>Dose-Limiting Toxicity</keyword>
  <keyword>Maximum Tolerated Dose</keyword>
  <keyword>Clinical Response</keyword>
  <keyword>Immune Response</keyword>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4 YU (Dose Level 1)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
        <group group_id="P2">
          <title>16 YU (Dose Level 2)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
        <group group_id="P3">
          <title>40 YU (Dose Level 3)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
        <group group_id="P4">
          <title>80 YU (Dose Level 4)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off study due to infection</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who received at least one dose of 4YU, 16YU, 40YU or 80YU.
Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
GI-6301 (Yeast Brachyury Vaccine): GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="32" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican, Puerto Rican, Cuban Central or So. Americ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>ECOG: 0 is normal activity. Fully active, able to carry on all pre-disease performance without restriction. 1 is symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and bale to carry out work of a light or sedentary nature (e.g., light housework, office work).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Colorectal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chordoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Breast</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pancreatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prostate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Urothelial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lung</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease at Study Entry</title>
          <description>Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response (≥30% decrease in the sum of greatest diameters; no new lesions), or progressive disease. Progressive disease is ≥20% increase in the sum of greatest diameters; new lesions.</description>
          <population>23 participants with carcinomas (solid tumors) and 11 participants with chordomas.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Carcinomas</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Stable disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chordomas</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Stable disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Cytotoxic Regimens</title>
          <description>Cytotoxic (i.e. poisonous to cancer cells)</description>
          <population>The module refers to 23 participants with carcinomas (solid tumors).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 regimen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 regimens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥3 regimens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Anatomical Location</title>
          <description>Sacral (i.e., sacrum), spinal (i.e., backbone), and clival (i.e. base of skull).</description>
          <population>The module refers to 11 participants with chordomas.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sacral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Therapy</title>
          <description>Surgery, radiotherapy and systemic therapy use surgical procedures, targeted therapy with radiation, steroids, and/or other immunosuppressive agents in an attempt to suppress one or more growing lesions.</description>
          <population>The module refers to 11 participants with chordomas.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Brachyury-Specific T-cell Responses</title>
        <description>A fluorescense activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.</description>
        <time_frame>Baseline (pre-vaccination) and approximately day 84 (after 6 vaccinations)</time_frame>
        <population>Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 31 of 34 patients to analyze brachyury-specific CD4 and CD8 T-cell responses.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Brachyury-Specific T-cell Responses</title>
          <description>A fluorescense activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.</description>
          <population>Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 31 of 34 patients to analyze brachyury-specific CD4 and CD8 T-cell responses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD107a + CD4 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD4 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD4 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD4 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD107a + CD8 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD8 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD8 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD8 T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any T-cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. A non-serious adverse event is any untoward medical occurrence.</description>
        <time_frame>4 years and 25 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. A non-serious adverse event is any untoward medical occurrence.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Clinical benefit is defined as partial response (PR) or stable disease (SD) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial response is ≥30% decrease in the sum of greatest diameters/no new lesions. Progressive disease is ≥20% increase in the sum of greatest diameters/new lesions. Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response, or progressive disease.</description>
        <time_frame>3 and 5 months restaging</time_frame>
        <population>One participant was not evaluable and came off study due to infection prior to restaging. Two participants were not evaluable due to withdrawal from the study or lack of measurable disease. Three patients with stable disease at 3 months elected to pursue alternate treatment and did not have 5 month restaging.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>Clinical benefit is defined as partial response (PR) or stable disease (SD) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial response is ≥30% decrease in the sum of greatest diameters/no new lesions. Progressive disease is ≥20% increase in the sum of greatest diameters/new lesions. Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response, or progressive disease.</description>
          <population>One participant was not evaluable and came off study due to infection prior to restaging. Two participants were not evaluable due to withdrawal from the study or lack of measurable disease. Three patients with stable disease at 3 months elected to pursue alternate treatment and did not have 5 month restaging.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable disease at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease at 5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response at 5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease at 5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)</title>
        <description>Blood samples will be collected via apheresis and analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC), Tregs, CD4 central memory (CD4 CM), CD4 effector memory (CD4 EM), CD4 terminal effector memory (CD4 EMRA), CD4 naïve, CD8 CM, CD8 EM, CD8 EMRA, and CD8 naïve cells. Significance of changes in immune cells was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
        <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
        <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)</title>
          <description>Blood samples will be collected via apheresis and analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC), Tregs, CD4 central memory (CD4 CM), CD4 effector memory (CD4 EM), CD4 terminal effector memory (CD4 EMRA), CD4 naïve, CD8 CM, CD8 EM, CD8 EMRA, and CD8 naïve cells. Significance of changes in immune cells was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
          <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
          <units>percentage of PBMC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median CD4 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.70" lower_limit="24.11" upper_limit="46.36"/>
                    <measurement group_id="O2" value="43.57" lower_limit="40.26" upper_limit="46.87"/>
                    <measurement group_id="O3" value="29.30" lower_limit="24.65" upper_limit="39.77"/>
                    <measurement group_id="O4" value="33.58" lower_limit="26.84" upper_limit="39.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.61" lower_limit="24.44" upper_limit="47.73"/>
                    <measurement group_id="O2" value="33.44" lower_limit="33.37" upper_limit="33.52"/>
                    <measurement group_id="O3" value="34.29" lower_limit="25.56" upper_limit="37.44"/>
                    <measurement group_id="O4" value="27.99" lower_limit="25.85" upper_limit="39.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.87" lower_limit="8.26" upper_limit="16.86"/>
                    <measurement group_id="O2" value="14.77" lower_limit="3.49" upper_limit="26.04"/>
                    <measurement group_id="O3" value="15.96" lower_limit="10.76" upper_limit="19.48"/>
                    <measurement group_id="O4" value="13.76" lower_limit="10.31" upper_limit="19.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.67" lower_limit="9.102" upper_limit="16.57"/>
                    <measurement group_id="O2" value="13.63" lower_limit="4.123" upper_limit="23.14"/>
                    <measurement group_id="O3" value="15.42" lower_limit="10.96" upper_limit="22.44"/>
                    <measurement group_id="O4" value="16.02" lower_limit="10.57" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median B cells Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" lower_limit="6.19" upper_limit="10.07"/>
                    <measurement group_id="O2" value="11.02" lower_limit="9.92" upper_limit="12.11"/>
                    <measurement group_id="O3" value="8.97" lower_limit="3.54" upper_limit="12.13"/>
                    <measurement group_id="O4" value="7.82" lower_limit="3.13" upper_limit="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median B cells d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" lower_limit="6.16" upper_limit="10.58"/>
                    <measurement group_id="O2" value="9.78" lower_limit="7.95" upper_limit="11.62"/>
                    <measurement group_id="O3" value="9.10" lower_limit="5.07" upper_limit="12.17"/>
                    <measurement group_id="O4" value="8.77" lower_limit="3.78" upper_limit="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Natural Killer (NK) Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="4.14" upper_limit="6.94"/>
                    <measurement group_id="O2" value="6.57" lower_limit="3.27" upper_limit="9.87"/>
                    <measurement group_id="O3" value="5.72" lower_limit="3.13" upper_limit="8.51"/>
                    <measurement group_id="O4" value="5.89" lower_limit="4.59" upper_limit="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Natural Killer (NK) d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" lower_limit="4.03" upper_limit="7.39"/>
                    <measurement group_id="O2" value="8.41" lower_limit="5.50" upper_limit="11.31"/>
                    <measurement group_id="O3" value="4.22" lower_limit="3.97" upper_limit="10.07"/>
                    <measurement group_id="O4" value="9.14" lower_limit="5.95" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Natural Killer T cell (NKT) Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.65" upper_limit="4.21"/>
                    <measurement group_id="O2" value="1.70" lower_limit="0.46" upper_limit="2.94"/>
                    <measurement group_id="O3" value="1.27" lower_limit="0.62" upper_limit="2.81"/>
                    <measurement group_id="O4" value="2.24" lower_limit="0.59" upper_limit="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Natural Killer T cell (NKT) d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.67" upper_limit="4.75"/>
                    <measurement group_id="O2" value="2.46" lower_limit="0.51" upper_limit="4.40"/>
                    <measurement group_id="O3" value="1.19" lower_limit="0.58" upper_limit="3.15"/>
                    <measurement group_id="O4" value="2.53" lower_limit="0.77" upper_limit="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median cDC Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.14" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.11" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.23" lower_limit="0.20" upper_limit="0.37"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.16" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median cDC d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.14" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.16" upper_limit="0.19"/>
                    <measurement group_id="O3" value="0.21" lower_limit="0.18" upper_limit="0.34"/>
                    <measurement group_id="O4" value="0.19" lower_limit="0.09" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median pDC Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.20" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.09" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.23" lower_limit="0.17" upper_limit="0.36"/>
                    <measurement group_id="O4" value="0.23" lower_limit="0.11" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median pDC d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.27" upper_limit="0.38"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.08" upper_limit="0.44"/>
                    <measurement group_id="O3" value="0.27" lower_limit="0.18" upper_limit="0.35"/>
                    <measurement group_id="O4" value="0.23" lower_limit="0.14" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median MDSC Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.98" lower_limit="2.96" upper_limit="19.19"/>
                    <measurement group_id="O2" value="8.53" lower_limit="4.30" upper_limit="12.76"/>
                    <measurement group_id="O3" value="8.47" lower_limit="5.98" upper_limit="14.54"/>
                    <measurement group_id="O4" value="13.73" lower_limit="5.41" upper_limit="17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median MDSC d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.41" lower_limit="4.82" upper_limit="18.78"/>
                    <measurement group_id="O2" value="10.78" lower_limit="5.98" upper_limit="15.58"/>
                    <measurement group_id="O3" value="7.55" lower_limit="4.95" upper_limit="12.16"/>
                    <measurement group_id="O4" value="12.77" lower_limit="6.64" upper_limit="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Treg Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.66" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.68" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.25" lower_limit="0.73" upper_limit="1.74"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.55" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Treg d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.78" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.42" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.12" lower_limit="0.83" upper_limit="1.71"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.45" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 EM Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.58" lower_limit="8.47" upper_limit="12.73"/>
                    <measurement group_id="O2" value="12.09" lower_limit="9.67" upper_limit="14.51"/>
                    <measurement group_id="O3" value="13.14" lower_limit="10.67" upper_limit="14.82"/>
                    <measurement group_id="O4" value="11.31" lower_limit="8.49" upper_limit="15.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 EM d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" lower_limit="7.49" upper_limit="13.48"/>
                    <measurement group_id="O2" value="10.72" lower_limit="9.20" upper_limit="12.25"/>
                    <measurement group_id="O3" value="12.50" lower_limit="11.33" upper_limit="13.63"/>
                    <measurement group_id="O4" value="9.76" lower_limit="7.21" upper_limit="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 CM Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.29" lower_limit="8.59" upper_limit="21.10"/>
                    <measurement group_id="O2" value="23.20" lower_limit="12.62" upper_limit="33.79"/>
                    <measurement group_id="O3" value="12.36" lower_limit="9.16" upper_limit="17.44"/>
                    <measurement group_id="O4" value="12.07" lower_limit="7.52" upper_limit="16.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 CM d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.80" lower_limit="9.75" upper_limit="24.37"/>
                    <measurement group_id="O2" value="16.51" lower_limit="10.97" upper_limit="22.06"/>
                    <measurement group_id="O3" value="12.78" lower_limit="10.53" upper_limit="17.98"/>
                    <measurement group_id="O4" value="11.36" lower_limit="6.00" upper_limit="14.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 EMRA Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.28" upper_limit="1.96"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.21" upper_limit="1.15"/>
                    <measurement group_id="O3" value="0.34" lower_limit="0.26" upper_limit="0.90"/>
                    <measurement group_id="O4" value="0.28" lower_limit="0.21" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 EMRA d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.26" upper_limit="0.70"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.24" upper_limit="1.43"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.23" upper_limit="0.56"/>
                    <measurement group_id="O4" value="0.38" lower_limit="0.21" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 naive Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" lower_limit="4.23" upper_limit="12.36"/>
                    <measurement group_id="O2" value="7.57" lower_limit="3.23" upper_limit="11.91"/>
                    <measurement group_id="O3" value="3.78" lower_limit="2.47" upper_limit="6.90"/>
                    <measurement group_id="O4" value="4.49" lower_limit="2.56" upper_limit="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD4 naive d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.48" lower_limit="4.14" upper_limit="12.76"/>
                    <measurement group_id="O2" value="5.41" lower_limit="2.08" upper_limit="8.73"/>
                    <measurement group_id="O3" value="3.99" lower_limit="3.49" upper_limit="7.51"/>
                    <measurement group_id="O4" value="6.08" lower_limit="3.15" upper_limit="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 EM Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" lower_limit="2.33" upper_limit="6.85"/>
                    <measurement group_id="O2" value="2.70" lower_limit="1.54" upper_limit="3.86"/>
                    <measurement group_id="O3" value="7.19" lower_limit="4.45" upper_limit="8.92"/>
                    <measurement group_id="O4" value="5.23" lower_limit="4.21" upper_limit="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 EM d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" lower_limit="2.85" upper_limit="6.87"/>
                    <measurement group_id="O2" value="3.33" lower_limit="2.61" upper_limit="4.06"/>
                    <measurement group_id="O3" value="6.60" lower_limit="4.12" upper_limit="10.78"/>
                    <measurement group_id="O4" value="6.11" lower_limit="3.91" upper_limit="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 CM Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.61" upper_limit="2.70"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.80" upper_limit="1.30"/>
                    <measurement group_id="O3" value="1.16" lower_limit="0.56" upper_limit="1.48"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.53" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 CM d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="0.81" upper_limit="2.43"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.53" upper_limit="1.19"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.80" upper_limit="1.44"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.32" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 EMRA Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="1.22" upper_limit="8.46"/>
                    <measurement group_id="O2" value="2.51" lower_limit="0.63" upper_limit="4.39"/>
                    <measurement group_id="O3" value="2.60" lower_limit="1.36" upper_limit="9.95"/>
                    <measurement group_id="O4" value="5.81" lower_limit="2.26" upper_limit="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 EMRA d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="1.40" upper_limit="7.35"/>
                    <measurement group_id="O2" value="3.24" lower_limit="0.69" upper_limit="5.80"/>
                    <measurement group_id="O3" value="3.31" lower_limit="1.14" upper_limit="10.71"/>
                    <measurement group_id="O4" value="5.06" lower_limit="3.11" upper_limit="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 naive Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" lower_limit="2.50" upper_limit="5.60"/>
                    <measurement group_id="O2" value="8.51" lower_limit="0.53" upper_limit="16.49"/>
                    <measurement group_id="O3" value="2.43" lower_limit="0.92" upper_limit="5.25"/>
                    <measurement group_id="O4" value="3.71" lower_limit="2.86" upper_limit="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median CD8 naive d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.58" upper_limit="6.21"/>
                    <measurement group_id="O2" value="6.20" lower_limit="0.30" upper_limit="12.09"/>
                    <measurement group_id="O3" value="3.12" lower_limit="1.00" upper_limit="5.82"/>
                    <measurement group_id="O4" value="3.44" lower_limit="2.06" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.5221</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD4 cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.25</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.50</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.8665</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD8 cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.88</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD8 cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.84</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.57</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.3052</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all B cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of B cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
            <method_desc>The reported p-value is representative of the changes in levels of B cells at dose level 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of B cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.65</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of B cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0698</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all NK cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of NK cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.74</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of NK cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of NK cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0127</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all NKT cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of NKT cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.41</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of NKT cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.07</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of NKT cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0654</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all cDC cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of cDC cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.21</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of cDC cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of cDC cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0457</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all pDC cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of pDC cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.55</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of pDC cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of pDC cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.7114</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all MDSC cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of MDSC cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of MDSC cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.91</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of MDSC cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.2666</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all Treg cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.88</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of Treg cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.45</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of Treg cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of Treg cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0076</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD4 EM cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 EM cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.22</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 EM cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.10</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 EM cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.7144</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD4 CM cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 CM cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.06</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 CM cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 CM cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.3741</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD4 EMRA cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The reported p-value is representative of the changes in levels of CD4 EMRA cells at dose level 1.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 EMRA cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 EMRA cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.3386</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD4 naive cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.88</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 naive cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0215</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 naive cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.65</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD4 naive cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.5076</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD8 EM cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 EM cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.68</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 EM cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.73</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 EM cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.6577</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD8 CM cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.88</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 CM cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.74</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 CM cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.20</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 CM cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.6295</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD8 EMRA cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 EMRA cells at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 EMRA cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 EMRA cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.8314</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all CD8 naive cells at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The reported p-value is representative of the changes in levels of CD8 naive cells at dose level 1.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.64</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 naive cells at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.30</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of CD8 naive cells at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Levels of Cytokines</title>
        <description>Blood samples were collected and changes in serum levels of cytokines interferon gamma (IFNg), Interleukin 10 (IL-10), Interleukin 12 (IL-12)p70, Interleukin 1b (IL-1b), Interleukin 2 (IL-2), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and tumor necrosis factor (TNF) were assessed by the multiplexed mesoscale assay. Significance of changes in serum levels of cytokines was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
        <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
        <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Levels of Cytokines</title>
          <description>Blood samples were collected and changes in serum levels of cytokines interferon gamma (IFNg), Interleukin 10 (IL-10), Interleukin 12 (IL-12)p70, Interleukin 1b (IL-1b), Interleukin 2 (IL-2), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and tumor necrosis factor (TNF) were assessed by the multiplexed mesoscale assay. Significance of changes in serum levels of cytokines was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
          <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median IFNg Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" lower_limit="2.47" upper_limit="6.12"/>
                    <measurement group_id="O2" value="3.56" lower_limit="2.99" upper_limit="4.13"/>
                    <measurement group_id="O3" value="2.805" lower_limit="1.97" upper_limit="3.6"/>
                    <measurement group_id="O4" value="4.47" lower_limit="4.05" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IFNg d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" lower_limit="2.17" upper_limit="3.17"/>
                    <measurement group_id="O2" value="2.83" lower_limit="2.62" upper_limit="3.04"/>
                    <measurement group_id="O3" value="2.84" lower_limit="1.76" upper_limit="4.71"/>
                    <measurement group_id="O4" value="4.9" lower_limit="2.91" upper_limit="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-10 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.17" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.215" lower_limit="0.2" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.21" lower_limit="0.17" upper_limit="0.28"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.31" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-10 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.23" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.285" lower_limit="0.28" upper_limit="0.29"/>
                    <measurement group_id="O3" value="0.24" lower_limit="0.18" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.26" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-12p70 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.22" lower_limit="0.2" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.2" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.2" lower_limit="0.2" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-12p70 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.2" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.2" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.2" lower_limit="0.2" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-1b Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.24" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.24" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.24" lower_limit="0.24" upper_limit="0.24"/>
                    <measurement group_id="O4" value="0.24" lower_limit="0.24" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-1b d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.24" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.24" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.24" lower_limit="0.24" upper_limit="0.24"/>
                    <measurement group_id="O4" value="0.24" lower_limit="0.24" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-2 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.64" upper_limit="2.40"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.64" upper_limit="0.64"/>
                    <measurement group_id="O3" value="0.64" lower_limit="0.64" upper_limit="0.64"/>
                    <measurement group_id="O4" value="0.64" lower_limit="0.64" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-2 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.64" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.64" upper_limit="0.64"/>
                    <measurement group_id="O3" value="0.64" lower_limit="0.64" upper_limit="0.64"/>
                    <measurement group_id="O4" value="0.64" lower_limit="0.64" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-6 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.71" upper_limit="2.85"/>
                    <measurement group_id="O2" value="0.78" lower_limit="0.66" upper_limit="0.9"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.52" upper_limit="1.3"/>
                    <measurement group_id="O4" value="2.37" lower_limit="0.69" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-6 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.74" upper_limit="1.23"/>
                    <measurement group_id="O2" value="0.855" lower_limit="0.76" upper_limit="0.95"/>
                    <measurement group_id="O3" value="1.04" lower_limit="0.54" upper_limit="1.97"/>
                    <measurement group_id="O4" value="2.84" lower_limit="0.90" upper_limit="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-8 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.45" lower_limit="16.84" upper_limit="487.6"/>
                    <measurement group_id="O2" value="43.87" lower_limit="16.05" upper_limit="71.69"/>
                    <measurement group_id="O3" value="37.49" lower_limit="18" upper_limit="91.01"/>
                    <measurement group_id="O4" value="63.52" lower_limit="33.7" upper_limit="560.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median IL-8 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.29" lower_limit="30.52" upper_limit="124.5"/>
                    <measurement group_id="O2" value="61.85" lower_limit="44.98" upper_limit="78.71"/>
                    <measurement group_id="O3" value="43.27" lower_limit="17.99" upper_limit="140.1"/>
                    <measurement group_id="O4" value="73.21" lower_limit="38.62" upper_limit="200.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median TNF Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" lower_limit="1.19" upper_limit="8.19"/>
                    <measurement group_id="O2" value="1.315" lower_limit="1.24" upper_limit="1.39"/>
                    <measurement group_id="O3" value="1.62" lower_limit="1.25" upper_limit="2.26"/>
                    <measurement group_id="O4" value="3.59" lower_limit="2.19" upper_limit="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median TNF d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" lower_limit="1.45" upper_limit="1.81"/>
                    <measurement group_id="O2" value="1.465" lower_limit="1.23" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.67" lower_limit="1.38" upper_limit="2.07"/>
                    <measurement group_id="O4" value="2.74" lower_limit="2.26" upper_limit="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.375</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IFNg cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.4808</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IFNg cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.7334</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IFNg cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.7109</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IFNg cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.4347</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IL10 cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL10 cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.748</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL10 cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.8203</p_value>
            <method>Wilcoxon test</method>
            <method_desc>The reported p-value is representative of the changes in levels of IL10 cytokines at dose level 4.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.5625</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IL12p70 cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL12p70 cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL12p70 cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.5</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL12p70 cytokines at dose level 14</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.6846</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IL1b cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL1b cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.5</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL1b cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL1b cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.4375</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IL-2 cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-2 cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-2 cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.75</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-2 cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.4525</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IL-6 cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
            <method_desc>The reported p-value is representative of the changes in levels of IL-6 cytokines at dose level 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.875</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-6 cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The reported p-value is representative of the changes in levels of IL-6 cytokines at dose level 3.</non_inferiority_desc>
            <p_value>0.4316</p_value>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-6 cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.9906</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all IL-8 cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.625</p_value>
            <method>Wilcoxon test</method>
            <method_desc>The reported p-value is representative of the changes in levels of IL-8 cytokines at dose level 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.791</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-8 cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.8203</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of IL-8 cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all TNF cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.875</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of TNF cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.9658</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of TNF cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.6523</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of TNF cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Soluble Cluster of Differentiation 27 (sCD27)</title>
        <description>Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27 was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
        <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
        <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Soluble Cluster of Differentiation 27 (sCD27)</title>
          <description>Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27 was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
          <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
          <units>U/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median sCD27 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.07" lower_limit="91.13" upper_limit="131"/>
                    <measurement group_id="O2" value="98.63" lower_limit="87.12" upper_limit="110.1"/>
                    <measurement group_id="O3" value="97.47" lower_limit="85.15" upper_limit="110.9"/>
                    <measurement group_id="O4" value="128.4" lower_limit="123.9" upper_limit="145.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median sCD27 d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.17" lower_limit="92.07" upper_limit="1112"/>
                    <measurement group_id="O2" value="92.07" lower_limit="83.3" upper_limit="100.8"/>
                    <measurement group_id="O3" value="101.7" lower_limit="98.85" upper_limit="105.1"/>
                    <measurement group_id="O4" value="133.1" lower_limit="129.7" upper_limit="155.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.2901</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all sCD27 cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.375</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of sCD27 cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.2036</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of sCD27 cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0742</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of sCD27 cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L)</title>
        <description>Blood samples were collected and changes in serum levels of the ratio of soluble sCD27:sCD40L was assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27:sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
        <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
        <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L)</title>
          <description>Blood samples were collected and changes in serum levels of the ratio of soluble sCD27:sCD40L was assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27:sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
          <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median sCD27:sCD40L Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.982" lower_limit="5.71" upper_limit="11.67"/>
                    <measurement group_id="O2" value="9.57" lower_limit="7.88" upper_limit="11.26"/>
                    <measurement group_id="O3" value="9.571" lower_limit="7.67" upper_limit="19.89"/>
                    <measurement group_id="O4" value="8.57" lower_limit="6.93" upper_limit="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median sCD27:sCD40L d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.428" lower_limit="4.79" upper_limit="9.43"/>
                    <measurement group_id="O2" value="8.294" lower_limit="7.29" upper_limit="9.29"/>
                    <measurement group_id="O3" value="10.47" lower_limit="6.63" upper_limit="19.38"/>
                    <measurement group_id="O4" value="8.257" lower_limit="6.96" upper_limit="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.1004</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all ratio sCD27:sCD40AL cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.625</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of ratio sCD27:sCD40L cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.6772</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of ratio sCD27:sCD40L cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.3008</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of ratio sCD27:sCD40L cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Soluble Cluster of Differentiation 40L (sCD40L)</title>
        <description>Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
        <time_frame>Pre (Baseline) and Day 85 after 6 vaccinations</time_frame>
        <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>4 YU (Dose Level 1)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>16 YU (Dose Level 2)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O3">
            <title>40 YU (Dose Level 3)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
          <group group_id="O4">
            <title>80 YU (Dose Level 4)</title>
            <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Soluble Cluster of Differentiation 40L (sCD40L)</title>
          <description>Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.</description>
          <population>Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median sCD40L Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="11.39" upper_limit="17.99"/>
                    <measurement group_id="O2" value="10.24" lower_limit="9.78" upper_limit="11.06"/>
                    <measurement group_id="O3" value="9.648" lower_limit="5.27" upper_limit="13.99"/>
                    <measurement group_id="O4" value="14.72" lower_limit="13.67" upper_limit="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median sCD40L d85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.23" lower_limit="11.96" upper_limit="19.42"/>
                    <measurement group_id="O2" value="11.14" lower_limit="10.84" upper_limit="11.43"/>
                    <measurement group_id="O3" value="9.854" lower_limit="5.86" upper_limit="14.52"/>
                    <measurement group_id="O4" value="18.57" lower_limit="16.09" upper_limit="19.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.0621</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of all sCD40L cytokines at dose levels 1, 3, and 4. We could not do dose level 2 as we only had data on 2 patients and need an n&gt;2 to do paired analyses.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.875</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of sCD40L cytokines at dose level 1.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.2402</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of sCD40L cytokines at dose level 3.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Significance was met if the unadjusted p-value was &lt;0.05 and &gt;1/2 of patients had a serum level change of &gt;25%.</non_inferiority_desc>
            <p_value>0.3008</p_value>
            <p_value_desc>The reported p-value is representative of the changes in levels of sCD40L cytokines at dose level 4.</p_value_desc>
            <method>Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 25 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4 YU (Dose Level 1)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
        <group group_id="E2">
          <title>16 YU (Dose Level 2)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
        <group group_id="E3">
          <title>40 YU (Dose Level 3)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
        <group group_id="E4">
          <title>80 YU (Dose Level 4)</title>
          <description>Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bone infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, lung obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, poor appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="33" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, nephrostomy tube site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, hemoglobinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder-Other, R knee swelling</sub_title>
                <description>gr. 1, unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other,R hand skin mass,excision 11/27/12</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="23" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Body aches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Erythema/redness R LE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, sebac cyst-back</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, R knee redness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, bruised R big toe</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, itching nose intermittent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, top R foot open wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Gulley</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-480-8870</phone>
      <email>gulleyj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

